

Maidstone and 
Tunbridge Wells

NHS Trust

Ref: FOI/CAD/ID 3705 & 4089

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

29 June 2017

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologics and biosimilar prescribing.

Could you please provide me with the numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs within the dermatology or gastroenterology departments?

- Abatacept (Orencia)*
- Adalimumab (Humira)*
- Apremilast (Otezla)*
- Certolizumab Pegol (Cimzia)*
- Etanercept (Enbrel)*
- Etanercept biosimilar (Benepali)*
- Fumaric Acid Esters N/A*
- Golimumab (Simponi)*
- Infliximab (Remicade)*
- Infliximab biosimilar (Inflectra)*
- Infliximab biosimilar (Remsima)*
- Rituximab (MabThera)*
- Secukinumab (Cosentyx)*
- Ixekizumab (Taltz)*
- Tocilizumab (RoActemra)*
- Ustekinumab (Stelara)*
- Vedolizumab (Entyvio)*

Please note the following information is a response to requests ID 3705 and ID 4089.

	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)	27	0	0
Adalimumab (Humira)	254	0	83
Apremilast (Otezla)	0	0	0

Certolizumab Pegol (Cimzia)	25	0	0
Etanercept (Enbrel)	183	0	0
Etanercept biosimilar (Benepali)	51	0	0
Golimumab (Simponi)	84	0	0
Infliximab (Remicade)	46	0	89
Infliximab biosimilar (Inflectra)	4	0	36
Infliximab biosimilar (Remsima)	45	0	90
Rituximab (MabThera)	102	0	0
Secukinumab (Cosentyx)	0	0	0
Ixekizumab (Taltz)	0	0	0
Tocilizumab (RoActemra)	54	0	0
Ustekinumab (Stelara)	7	0	0
Vedolizumab (Entyvio)	0	0	15